AmeriPath Appoints Medical Director of Its Center for Advanced Diagnostics; Will Serve as Primary Hematopathology Evaluation and Consultation Source.Business Editors/Health & Medical Writers RIVIERA BEACH, Fla.--(BUSINESS WIRE)--Dec. 15, 2000 AmeriPath Inc, (Nasdaq:PATH), the largest company focused on providing anatomic pathology, cancer diagnostic and related healthcare information services See Information Systems. , announced today the appointment of Russell L. Maiese, M.D. as Medical Director and the Director of Hematopathology at the Company's Center for Advanced Diagnostics, located in Orlando, Florida. The Center for Advanced Diagnostics (CAD) offers a full array of diagnostics for hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. and solid tissue malignancies, including molecular genetics molecular genetics n. The branch of genetics that deals with hereditary transmission and variation on the molecular level. , cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. , flow cytometry flow cytometry (flōˑ sī·t  ˑ·m , specialized immunohistochemistry, and minimal residual disease residual disease Oncology Malignant cells or neoplasia that remains after any form–chemotherapy, surgery, RT–of 1º treatment detection. Dr. Maiese is board certified board certified, adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. in anatomic and clinical pathology, with certification in the subspecialty subspecialty, n a limited portion of a narrowly defined professional discipline. E.g., surgery is a specialty of medicine and pediatric vascular surgery is a subspecialty. of hematopathology. He has most recently served as the Director of Clinical Consultative Services for Cytometry Associates, in West Palm Beach, Florida West Palm Beach, also known as West Palm, is the most populous city in Palm Beach County, Florida, USA. The city is also the oldest incorporated municipality in South Florida. According to the University of Florida's 2006 estimates, the city had a population of 107,617. . Prior positions included hematopathologist for Dianon Systems, Stratford, Connecticut, as well as Assistant Professorship in the Department of Pathology at the University of Florida University of Florida is the third-largest university in the United States, with 50,912 students (as of Fall 2006) and has the eighth-largest budget (nearly $1.9 billion per year). UF is home to 16 colleges and more than 150 research centers and institutes. College of Medicine in Gainesville, Florida, and the University of Texas Southwestern Medical School Ranking and selectivity The medical school ranked 19th in the 2008 U.S. News and World Report ranking of the top medical schools in the research category (ranked 6th among public medical schools), ranked 18th in primary care category, and ranked 21st in terms of research in Dallas, Texas. Dr. Maiese has authored numerous published articles and professional abstracts. CAD's staff includes several doctoral scientists with extensive experience and credentials in molecular genetics, cytogenetics, flow cytometry, and pathology. Pathologists, board certified in anatomic and clinical pathology, with subspecialty expertise in hematopathology, cytopathology, and solid tumor diagnosis complete the medical and scientific staff. In addition to diagnostic testing for both AmeriPath and non-AmeriPath physicians, hospitals, and other healthcare providers, CAD is able to perform developmental work for diagnostic manufacturers, clinical research organizations (CROs), and large pharmaceutical companies using AmeriPath's unparalleled access to normal, abnormal, and cancerous tissues. AmeriPath, Inc. is the nation's largest company focused on providing anatomic pathology, cancer diagnostic and related healthcare information services to physicians, hospitals, national clinical laboratories and managed care organizations. The company's physicians provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers. The statements contained in this press release are "forward-looking statements" which are based on current beliefs and expectations. Past performance is not necessarily indicative of future results. In addition, forward-looking statements - which are identified by words such as "may", "should", "believe," "expect," "anticipate" and similar expressions -- are subject to a number of risks and uncertainties which could cause actual results to differ materially from historical results or those expected or anticipated. These include risks and uncertainties relating to satisfaction of closing conditions, demand for pathology services, pricing, federal and state regulation (and compliance), reimbursement rates, government and third party payments, the ability to attract, motivate, and retain pathologists, dependence upon pathologists and contracts, the development and expansion of managed care and national clinical lab contracts, completion and integration of acquisitions and affiliations (and achievement of planned or expected synergies), competitive factors and technology. Further information regarding risks, uncertainties and other factors that could affect the Company's financial results, or could cause actual results to differ materially from those expected or anticipated, are included in the Company's Form 10-K for the year ended December 31, 1999 and subsequent filings with the SEC. Editor's Note: This release is also available at http://www.ameripath.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion